Raymond Heung, MD
Hematology & Oncology · San Diego, CANPI 1699772756
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.8%), consulting fees and education — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by AstraZeneca at 51.0% of the total. Reporting peaked in 2019 at $3,661 and has fallen 98.9% since, to $40 in 2025.
Across 162 payments — averaging $34.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Amgen$414
- Johnson & Johnson$224
- Boehringer Ingelheim$183
- Eisai Inc.$162
- Astellas Pharma US Inc$161
- plus $2K from 31 others
What the payments were for
- Consulting fees$2,11538%
- Food & beverage$3,26459%
- Education$1723%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 39 | $2,831 |
| Amgen | 19 | $414 |
| Johnson & Johnson(2 entities) | 8 | $224 |
| Boehringer Ingelheim | 10 | $183 |
| Eisai Inc. | 7 | $162 |
| Astellas Pharma US Inc | 3 | $161 |
| Incyte Corporation | 5 | $121 |
| Bayer | 6 | $116 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Rigel Pharmaceuticals, Inc. | 5 | $100 |
| Merck | 5 | $98 |
| Exelixis Inc. | 6 | $97 |
| Novo Nordisk | 5 | $90 |
| Amarin Pharma, Inc. | 4 | $82 |
| Mirati Therapeutics, Inc. | 3 | $68 |
| Seagen Inc. | 4 | $62 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $60 |
| AbbVie | 3 | $60 |
| Gilead | 3 | $54 |
| Pfizer | 2 | $48 |
| Teva Pharmaceuticals USA, Inc. | 2 | $39 |
| EMD Serono, Inc. | 2 | $39 |
| Daiichi Sankyo Inc. | 2 | $35 |
| Novartis | 2 | $32 |
| Sanofi Pasteur Inc. | 2 | $31 |
| Bristol Myers Squibb | 1 | $27 |
| EUSA Pharma (US) LLC | 1 | $27 |
| Grifols USA, LLC | 1 | $23 |
| Myovant Sciences Inc. | 1 | $23 |
| Puma Biotechnology, Inc. | 1 | $22 |
| Sanofi | 1 | $21 |
| Philips North America LLC | 1 | $19 |
| Clovis Oncology, Inc. | 1 | $18 |
| Mylan Institutional Inc. | 1 | $17 |
| Taiho Oncology, Inc. | 1 | $17 |
| Dova Pharmaceuticals | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,550 in reported general payments places this provider in the 55th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 49 | $60,098 |
| RybelsusSemaglutide | 37 | $42,670 |
| JardianceEmpagliflozin | 41 | $33,322 |
| FarxigaDapagliflozin Propanediol | 30 | $21,617 |
| ProliaDenosumab | 13 | $20,949 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $19,053 |
| GlyxambiEmpagliflozin/Linagliptin | 20 | $18,867 |
| EliquisApixaban | 18 | $13,158 |
| Atrovent HfaIpratropium Bromide | 12 | $11,362 |
| MyrbetriqMirabegron | 20 | $11,336 |
| VascepaIcosapent Ethyl | 30 | $9,822 |
| Serevent DiskusSalmeterol Xinafoate | 12 | $5,116 |
| Insulin Lispro Protamine MixInsulin Lispro Protamin/Lispro | 12 | $3,847 |
| Icosapent Ethyl | 25 | $3,570 |
| Qvar RedihalerBeclomethasone Dipropionate | 11 | $3,171 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $90 | $102,76886 claims |
| Boehringer IngelheimJardiance, Glyxambi | $183 | $52,18961 claims |
| AstraZenecaFarxiga | $2,831 | $21,61730 claims |
| AmgenProlia | $414 | $20,94913 claims |
| PfizerEliquis | $48 | $13,15818 claims |
| Astellas Pharma US IncMyrbetriq | $161 | $11,33620 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $39 | $3,17111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in San Diego
- Wendy LevinSan Diego$760K
- Rana McKaySan Diego$530K
- Ezra CohenSan Diego$495K
- Annette von DrygalskiSan Diego$406K
- Lyudmila BazhenovaSan Diego$328K
- Sandip PatelSan Diego$295K
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.